Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: SYK stock price vs AORT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AORT's multiple
Needs AORT P/E.
Implied fair value · at SYK's multiple
Needs SYK P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
STRYKER CORP · implied price per share
Bear
$88.62
Base
$109.63
Bull
$137.00
ARTIVION, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
SYK vs ABT
JOHNSON & JOHNSON
SYK vs JNJ
BAXTER INTERNATIONAL INC
SYK vs BAX
INTUITIVE SURGICAL INC
SYK vs ISRG
ALIGN TECHNOLOGY INC
SYK vs ALGN
Merck & Co., Inc.
SYK vs MRK
BOSTON SCIENTIFIC CORP
SYK vs BSX
ZIMMER BIOMET HOLDINGS, INC.
SYK vs ZBH
TELEFLEX INC
SYK vs TFX
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe the market will re-rate SYK closer to AORT earnings multiples given its stronger margins and ROIC, then buy SYK because it trades at 41.0x P/E versus AORT's 179.3x and shows materially higher operating and net margins (SYK operating margin 19.5% vs AORT 7.6%; net margin 12.9% vs 2.2%), implying substantial upside; if you doubt a re-rating or require clearer FCF evidence, wait for improved F-score or FCF disclosure.
SYK's implied P/E-derived price ($1,506.40) is far above its current price ($344.60), implying a 337.1% upside versus current levels. The primary driver is a large P/E divergence (SYK 41.0x vs AORT 179.3x) rather than revenue multiple differences.
Supporting Metrics
